$TRVN (Part 2/2) Some plan on selling some shares before approval and keep the rest as a long-term hold. What is a reasonable sell price? (See results from poll: trvn.weebly.com/discussions...) Is it possible the sell price is too low? 1. With so many Phase I, II, III studies halted because of COVID-19, might this imply that there maybe a temporary lull in NDA submissions? If so, how does this help Oli? (For institutional buyers who specialize in biotech, perhaps this means fewer choices on the playing field and hence, possibly, more focus on TRVN?) 2. Oli is not needed for COVID-19 patients. However, COVID-19 does cause severe respiratory stress possibly with long-term implications. This could imply that the mkt for Oli will unfortunately grow because of need. Also, when given a choice, families and patients will chose oli over morphine. Has your opinion changed since the poll results from March 2020?